Steven M. Keller MD
|
Steven M. Keller, MD
Montefiore-Einstein Medical Center Faculty Appointments
|
| Dec. 2000- Apr. 2005: | Co-Director, Residency Program, Department of Cardiothoracic Surgery Montefiore Medical Center, Bronx, N.Y. |
||
| Apr. 2000-Present: | Clinical Professor of Cardiothoracic Surgery Albert Einstein College of Medicine, New York, N.Y. |
||
| Feb. 1995-Apr. 2000: | Associate Professor of Cardiothoracic Surgery Albert Einstein College of Medicine, New York, N.Y. |
||
| Jan. 1993-Feb. 1995: | Co-Director, Residency Program, Department of Cardiothoracic Surgery The Mount Sinai Medical Center, New York, N.Y. |
||
| Jan. 1993-Feb. 1995: | Associate Professor of Cardiothoracic Surgery Mount Sinai School of Medicine, New York, N.Y. |
||
| Sept. 1992-Dec. 1992: | Chief, Thoracic Surgical Oncology Member, Fox Chase Cancer Center, Philadelphia, Penn. |
||
| July 1987-Aug. 1992: | Assistant Professor of Surgery Temple University, Philadelphia, Penn. |
||
| July 1986-June 1987: | Instructor in Thoracic Surgery Cornell University School of Medicine, New York, N.Y. |
||
| July 1984-June 1985: | Instructor in Surgery The Mount Sinai School of Medicine, New York, N.Y. |
Hospital Appointments
| Oct. 2003-Apr. 2005: | Interim Chair, Department Cardiothoracic Surgery Montefiore Medical Center, Bronx, N.Y. |
||
| July 2002-Oct. 2003: | Vice-Chair Department Cardiothoracic Surgery Montefiore Medical Center, Bronx, N.Y. |
||
| Dec. 2000-Present: | Chief, Division of Thoracic Surgery Montefiore Medical Center, Bronx, N.Y. |
||
| Feb. 1995-Dec. 2000: | Director, The David B. Kriser Lung Cancer Center Beth Israel Medical Center, New York, N.Y. |
||
| Feb. 1995-Dec. 2000: | Chief, Division of General Thoracic Surgery Beth Israel Medical Center, New York, N.Y. |
||
| Jan. 1993-Feb. 1995: | Chief, Division of General Thoracic Surgery Mount Sinai School of Medicine, New York, N.Y. |
||
| Sept. 1992-Dec. 1992: | Chief, Thoracic Surgical Oncology Member, Fox Chase Cancer Center, Philadelphia, Penn. |
||
| July 1987-Sept. 1992: | Chief, Thoracic Surgical Oncology Associate Member, Fox Chase Cancer Center, Philadelphia, Penn. |
Societies
American College of Surgeons, Fellow
American College of Chest Physicians, Fellow
American Society of Clinical Oncology
Association for Academic Surgery
General Thoracic Surgery Club
Society of Surgical Oncology
Society of Thoracic Surgeons
Organizations
Eastern Cooperative Oncology Group
Chair, Thoracic Surgery Subcommittee,
July 1988-June1992; Oct. 2001-Present
National Committees
| Dec. 2005-Present | Member, Myasthenia Gravis Data Safety Monitoring Committee (NIH) | ||
| July 1993-June 1995 | Chairman, Section on Cancer, American College of Chest Physicians | ||
| July 1992-June 1996 | Member, Cancer Research Manpower Training, Review Committee, National Cancer Institute | ||
| July 1991 | Ad Hoc Member, Cancer Research Manpower, Review Committee, National Cancer Institute | ||
| July 1991-July1995 | Steering Committee on Cancer, American College of Chest Physicians | ||
| July 1990-July 1995 | Ad Hoc Member of NCI Site Review Team |
Hospital Committees
| Jan. 2003-Present | Chair, Quality Review Committee, Department Cardiothoracic Surgery | ||
| Dec. 2002-Present | Chair, Protocol Review Committee, Albert Einstein College of Medicine Cancer Center | ||
| Dec. 2003-Dec. 2005 | Member, Montefiore Quality Council | ||
| Jan. 2002-Jan. 2003 | Quality Review Committee, Montefiore Medical Center |
Research Interests
Adjuvant Therapy of Lung Cancer
Hyperhidrosis
Grants and Awards
| July 1990-June1992 | P.I., American Cancer Society Clinical Oncology Career Development Award, $90,000 |
||
| July 1989-June1990 | P.I., American Lung Association Research Grant, $13,881 |
Editorial Boards
Annals of Surgical Oncology
Cancer (Ad Hoc)
Annals of Thoracic Surgery
Chest
Lung Cancer
Education and Training
| 1975: | Rensselaer Polytechnic Institute, BS Biology Troy, N.Y. |
||
| 1977: | Medical Degree Albany Medical College of Union University, New York, N.Y. *Six-year combined biomedical program. |
||
| July 1977-June 1978: | Intern, Department of Medicine Long Island Jewish Hospital, New Hde Park, N.Y. |
||
| July 1979-June 1985: | Resident, Department of Surgery Mount Sinai Hospital, New York, N.Y. |
||
| July 1985-June 1987: | Fellow, Cardiothoracic Surgery New York Hospital and Memorial Sloan-Kettering Cancer Center, New York, N.Y. |
||
| July 1981-June 1983: | Clinical Associate, Surgery Branch National Cancer Institute, National Institutes of Health, Bethesda, MD |
Board Certifications
American Board of Surgery, 1986
American Board of Thoracic Surgery, 1988
Honors and Awards
| Feb. 2000 | Maxwell Chamberlain Paper Society of Thoracic Surgeons Annual Meeting |
||
| June 1985 | Bella Trachtenberg Award for House-Staff Excellence Mount Sinai Hospital |
||
| Aug. 1975 | Student Research Project Award Albany Medical College |
Selected Publications
Journals
1. Keller SM, Papazoglou S, McKeever P, Baker A, Roth JA. Late occurrence of malignancy in a ganglioneuroma 19 years following radiation therapy to a neuroblastoma. J Surg Onc 1984;25:227-31
2. Keller SM, Rosenbaum RC, Rosenberg SA. The significance of bone-scan abnormalities in patients with primary osteogenic sarcoma. J Surg Onc 1984;26:122-9
3. Keller SM, Goldfarb AB. Emphysematous cholecystitis: a case report. Contemp Surg 1985;26:51-3
4. Keller SM, Papa M, Wilder JR. Inferior vena cava interruption. Mt Sinai J Med 1985;52(5):353-7
5. Keller SM, Zisbrod Z, Goldfarb AB. Solitary nonparasitic liver cysts. NYS J Med 1985;85:95-6
6. Inculet RI, Keller SM, Dwyer A, Roth JA. Evaluation of non-invasive tests for the preoperative staging of carcinoma of the esophagus: a prospective study. Ann Thorac Surg 1985;40(6):561-65
7. Keller SM, Waxman JS, Kim U. Benign symmetrical lipomatosis. South Med J 1986;79(11):1428-9
8. Keller SM, Kaiser LR, Martini N. The azygos lobe of the lung. Contemp Surg 1986 29:33-5
9. Keller SM, Markovitz LJ, Wilder JR, Aufses AH Jr. Emergency surgery in patients aged over 70 years. Mt Sinai J Med 1987;51(1):25-8
10. Keller SM, Markovitz LJ, Wilder JR, Aufses AH Jr. Emergency and elective surgery in patients over Age 70 years. Am Surg 1987;53:635-40
11. Keller SM, Groshen S, Martini N, Kaiser LR. Blood transfusion and lung cancer recurrence. Cancer 1988;62:606-10
12. Keller SM, Kaiser LR, Martini N. Bilobectomy for bronchogenic carcinoma. Ann Thorac Surg 1988;45:62-5
13. Kaiser LR, Fleshner P, Keller SM, Martini N. Significance of extramucosal residual tumor at the bronchial resection margin. Ann Thorac Surg 1989;47:265-9
14. Alosco T, Eisenberg BL, Keller SM. Retrotracheal goiter. South Med J 1990;83:239-40
15. Keller SM, Taylor DD, Weese JL. In-vitro killing of human malignant mesothelioma by photodynamic therapy. J Surg Res 1990;48:337-40
16. Palazzo JP, Garcia-Palazzo LE, Reyes JM, Keller SM. Cardiac metastases from a breast tumor with features of stromal sarcoma: a histologic, ultrastructural, and cell culture study. Surg Pathol 1990;3:227-34
17. Miura L, Siegfried JM, Resau J, Keller SM, Zhou J-Y, Testa JR. Chromosome alterations in 21 non-small cell lung carcinomas. Genes Chrom Cancer 1990;2:328-38
18. Horowitz J, Kline DG, Keller SM. Schwannoma of the brachial plexus mimicking an apical lung tumor. Ann Thorac Surg 1991;52:555-6
19. Pelton JJ, Kowalyshyn MJ, Keller SM. Intrathoracic organ injury associated with photodynamic therapy. J Thorac Cardiovasc Surg 1992;103:1218-23
20. Carp NZ, Ellison DD, Brophy PF, Watts P, Chang MC, Keller SM. DNA content in correlation with postsurgical stage in non-small cell lung cancer. Ann Thorac Surg 1992;53:680-3
21. Langer CJ, Keller SM, Erner S. Thymic hyperplasia with hemorrhage simulating recurrent Hodgkin disease after chemotherapy-induced complete remission. Cancer 1992;70(8):2082-6
22. Brophy PF, Keller SM. Adriamycin enhanced in vitro and in vivo photodynamic therapy of mesothelioma. J Surg Res 1992;52:631-34
23. Curran WJ, Herbert SH, Stafford PM, Sandler HM, Rosenthal S, McKenna WG, Hughes E, Dougherty MJ, Keller SM. Should patients with post-resection locoregional recurrence of lung cancer receive aggressive therapy? Int J Rad Oncol Biol Phys 1992;24:25-30
24. Sauter ER, Keller SM, Curran WJ, Russo J, Langer CJ. Radiation-induced chest-wall chondrosarcoma following surgical resection and radiotherapy for non-small cell lung cancer. J Nat Cancer Inst 1993;85:162-3
25. Keller SM. Current and future therapy of malignant pleural effusion. Chest 1993;103:63S-7S
26. Siegfried JM, Hunt JD, Zhou J, Keller SM, Testa JR. Cytogenetic abnormalities in non-small cell lung carcinoma: detection in conventional and feeder-cell layer cultures. Genes Chrom Cancer 1993; 6:30-8
27. Fowler WC, Langer CJ, Curran WJ, Keller SM. Postoperative complications following combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 1993; 55:986-9
28. Langer CJ, Curran Jr WJ, Keller SM, Catalano R, Fowler W, Blankstein K, Litwin S, Bagchi P, Nash S, Comis R. Report of Phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIb and bulky IIIa non-small cell lung cancer. Int J Radiation Oncol Biol Phys 1993;26:469-78
29. Pelton JJ, Fish DJ, Keller SM. Epidural narcotic analgesia following thoracotomy. S Med J 1993; 86:1106-9
30. Keller SM. Treatment of intrathoracic recurrent non-small cell lung cancer. Sem Oncol 1993; 20:446-50
31. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Research 1993; 53:4349-55
32. Gwin JL, Keller SM. Blood transfusion practices in general thoracic surgery. J Surg Oncol 1993; 54:34-7
33. Sauter ER, Keller SM, Erner S. HER-2/neu: A differentiation marker in adenocarcinoma of the esophagus. Cancer Letters 1993; 75:41-4
34. Sauter ER, Coia LR, Keller SM. Preoperative high dose radiation and chemotherapy in adenocarcinoma of the esophagus and esophago-gastric junction. Ann Surg Oncol 1994; 1:5-10
35. Keller SM. Adjuvant therapy for mesothelioma. Chest Surg Clin N Amer 1994; 4:127-35
36. Gwin JL, Klein-Szanto AJP, Zhang S-Y, Agarwal P, Rogatko A, Keller SM. Loss of blood group antigen A is not a poor prognostic factor in non-small cell lung cancer. Ann Surg Oncol 1994;1:423-7
37. Testa JR, Siegfried JM, Liu Z, Hung JD, Feder MM, Litwin S, Zhou J-Y, Taguchi T, Keller SM. Cytogenic analysis of 63 non-small cell lung carcinomas: Recurrent chromosome alterations amid frequent and widespread genomic upheaval. Genes Chrom Cancer 1994;11:178-94
38. Dalton R, Keller SM. Survival following resection of clinically occult N2 non-small cell lung cancer. J Cardiovasc Surg 1994;35(Suppl. 1 to No.6):13-7
39. Keller SM, Carp NZ, Levy MH, Rosen SM. Chronic post-thoracotomy pain. J Cardiovasc Surg 1994;35(Suppl. 1 to No.6):161-4
40. Keller SM. Photodynamic therapy of thoracic neoplasms: biology and clinical application. Chest Surg Clin N Amer 1995;5:121-37
41. Sauter ER, Keller SM, Erner S. P53 correlates with improved survival in patients with esophageal adenocarcinoma. J Surg Oncol 1995;58:269-73
42. Keller SM. Advances in lung cancer. Mt Sinai J Med 1995;62:198-203
43. Algan Ö, Coia LR, Keller SM, Engstrom PF, Hanks GE, Schultheiss TE. Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy. Int J Radiation Oncol Biol Phys 1995;32:753-61
44. Sauter ER, Langer C, Coia L, Goldberg M, Keller SM. Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 1995;60:100-5
45. Sauter ER, Mandeli J, Keller SM. P53 correlates with disease progression in patients with non-small cell lung cancer. Surg Oncol 1995;4:157-61
46. Langer CJ, Curran WJ, Keller SM, et al. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. Cancer J Sci Amer 1996;2:99-105
47. Spivak H, Keller SM. Spontaneous pneuomothorax in the AIDS population. Am Surg 1996;62:753-6
48. Feder M, Siegfried JM, Balshem A, Litwin S, Keller SM, Liu Z, Testa JR. Clinical relevance of chromosome abnormalities in non-small cell lung cancer. Cancer Genet Cytogenet 1998;102:25-31
49. Keller SM, Ryan LM, Coia LR, Dang P, Vaughn DJ, Diggs C, Weiner LM, Benson AB. High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction: Results of a Phase II study of the Eastern Cooperative Oncology Group. Cancer 1998;83:1908-16
50. Prasad ML, Charney D, Sarlin J, Keller SM. Pulmonary immunocytoma with massive crystal storing histiocytosis: a case report with review of the literature. Am J Path 1998;22:1148-53
51. Ginsberg R, Bunn P, Keller S. New approaches for the treatment of resectable non-small-cell lung cancer. From Research to Practice 1999;1:13-9
52. Abolhoda A, Keller SM. Thoracic surgical spectrum of HIV infection. Sem Resp Inf 1999;14:359-65
53. Keller SM. Adjuvant therapy for resectable non-small cell lung cancer. Curr Opin Oncol 2000;12:149-55
54. Keller SM. Adjuvant therapy of non-small cell lung cancer. Clin Lung Cancer 2000;1:269-74
55. Keller SM, Adak S, Wagner H, Johnson D, and the Eastern Cooperative Oncology Group. Complete mediastinal lymph node dissection improves survival in patients with resected stages II and IIIa non-small cell lung cancer. Ann Thor Surg 2000;70:358-66
56. Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH for the Eastern Cooperative Oncology Group. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: An Intergroup trial. N Engl J Med 2000;343:1217-22
57. Keller SM, Johnson DH. Adjuvant chemotherapy for completely resected non-small-cell lung cancer (letter). N Engl J Med 2001;344:689-690
58. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingstone RB, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer: Report from a prospective randomized trial of postoperative adjuvant therapy (E3590). J Clin Oncol 2001;19:448-57
59. Keller SM. Commentary: complete mediastinal lymph node dissection - does it make a difference? Lung Cancer 2002;36:7-8
60. Keller SM, Vangel MG, Adak S, Wagner H, Schiller JH, Herskovic A, Komaki R, Brooks BJ, Perry MC, Marks RS, Livingston RB, Johnson DH for the Eastern Cooperative Oncology Group. The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer 2002;37:303-309
61. Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH for the Eastern Cooperative Oncology Group. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer. Am J Oncol Rev 2002:1;39-46
62. Khandani AH, Keller SM, Blaufox MD. F-18 Fluorodeoxyglucose (FDG) PET: False positive lung cancer. Sem Nucl Med 2002;32:212-3
63. Haigentz M, Keller SM. Evaluation of mediastinal lymph nodes in patients with non-small cell lung cancer. Lung Cancer: Principles and Practice Updates 2002;2:1-11
64. Granone P, Keller S, Trodella L, Cesario A, Margaritor S, Porziella V, Valente S, Maria Corbo G, d'Angelillo R. Postoperative radiotherapy in completely resected, early-stage, non-small-cell lung cancer: reflections and future directions. Lancet Oncol 2002;3:589-590
65. Rajdev L, Keller SM. Neoadjuvant and adjuvant therapy of non-small cell lung cancer. Surg Oncol 2002;11:243-253
66. Pisch J, Moskovitz T, Esik O, Homel P, Keller S. Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity. Path Oncol Res 2002;8:163-169
67. Keller SM, Vangel MG, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Marks RS, Livingston RB, Johnson DH for the Eastern Cooperative Oncology Group. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer 2003;42:79-86
68. Sawabata N, Keller SM, Matsumura A, Kawashima O, Osaka Y, Maeda H, Fukai S, Kawahara M, for The Japan National Chest Hospital Study Group for Lung Cancer. Combined modality therapy of non-small cell lung cancer: A rationale for nodal exploration prior to surgery. Lung Cancer 2003;42:69-77
69. Keller SM. Adjuvant therapy for locally advanced non-small cell lung cancer. Lung Cancer 2003;42(Suppl 2):S29-34.
70. Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic AM, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH. Prolonged survival in patients with resected non-small cell lung cancer (NSCLC) and single level N2 disease. J Thorac Cardiovasc Surg 2004;128:124-129
71. Belbin TJ, Gaspar J, Haigentz, Perez-Solar R, Keller SM, Prystowsky MB, Childs G, Socci ND. Indirect measurements of differential gene expression with cDNA microarrays. BioTechniques 2004;36:310-314
72. Wakelee H, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH, for the Eastern Cooperative Oncology Group (ECOG). Adjuvant radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIa non-small cell lung cancer (NSCLC) does not lead to higher than expected risk of death from intercurrent disease (DID). Lung Cancer 2005;48:389-97
73. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Pérez-Soler R, Band Horwitz S. Enhancement of the therapeutic efficacy of Taxol by the mitogen-activated protein kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Research 2005;65:2854-2860
74. Dubey S, Stephenson P, Levy DE, Miller J, Keller SM, Schiller JH, Johnson DH, Kolesar JM. EGFr dinucleotide repeat polymorphism as prognostic indicator in non-small cell lung cancer. J Thorac Onocol 2006;1:406-412
75. Khandani AH, Whitney KD, Keller SM, Isasi CR, Blaufox D. Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer. Nucl Med Commun 2007;28:173-7
76. Khan AM, Kaoutar T, Nataraj S, Dingming Y, Keller S, Berman A. A localized pleural based mass with intense uptake on PET scan. Chest 2007;131:294-99
77. Costa DB, Li S, Kocher O, Feins RH, Keller SM, Schiller JH, Johnson DH, Tenen DG, Halmos B. Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down regulation in squamous cell carcinoma: a correlative study of E3590. Lung Cancer 2007;56:97-103
78. Legrier M-E, Yang C-P.H, Yan H-G, Lopez-Barcons L, Keller SM, Perez-Solar R, Horwitz SB, McDaid HM. Targeting protein translation in human non-small cell lung cancer via combined ME and mTOR suppression. (Cancer Res in press)
79. Kolesar JM, Breunig AC, Stephenson P, Marsh S, Miller JA, Vangel MG, McLeod HL, Johnson DH, Keller SM, Lafferty JS, Schiller JH. The NQO1*2/p53 Wild-Type Genetic Combination is a Predictor of Poor Survival in Patients Who Received Adjuvant Radiation and Chemotherapy Following Resection of Stages II and IIIa Non-Small Cell Lung Cancer. (Submitted)
Book Chapters
1. Schor J, Keller SM. Surgical treatment of non-small cell lung Cancer. In: Current Clinical Oncology: Lung Cancer. Bruce Johnson, David Johnson, eds. John Wiley and Sons, Somerset, New Jersey, 1994
2. Keller SM. Lung cancer: Surgery. In: Current Therapy in Hematology-Oncology, Fifth Edition. John Kelton, Paul Carbone, eds. Mosby Year Book, Inc., St. Louis, MO, 1995
3. Keller SM. Mediastinal lymph node dissection. In: Lung Cancer: Principles and Practice. Harvey Pass, ed. J.B. Lippincott Company, Philadelphia, 1995
4. Bonomi P, Keller SM, Wagner H. Non-small cell lung cancer. In: Cancer Management: A Multidisciplinary Approach. Richard Pazdur, Lawrence Coia, Lawrence Wagman, William Hoskins, eds. PRR, New York, 1996
5. Bonomi P, Keller SM, Wagner H. Small-cell lung cancer. In: Cancer Management: A Multidisciplinary Approach. Richard Pazdur, Lawrence Coia, Lawrence Wagman, William Hoskins, eds. PRR, New York, 1996
6. Edhe M, Keller SM. Minimally invasive approaches to diagnosis and management of neoplastic disease of the thorax and abdomen. In: Cancer Medicine. James F. Holland, Emil Frei III, eds. Lea & Febiger, Philadelphia 1997
7. Keller SM. Lung cancer: Surgery. In: Current Therapy in Adult Medicine. Jerome P. Kassirer, Harry L. Greene, II, eds. Mosby Year Book, Inc., Philadelphia, PA, 1997
8. Keller SM. Mediastinal lymph node dissection. In: Mastery of Cardiothoracic Surgery. Larry R. Kaiser, Irving L. Kron, Thomas L. Spray, eds. Little, Brown, and Company, Boston 1997
9. Keller SM. K Katariya. Primary lung tumors other than bronchogenic carcinoma: Benign and malignant. In: Pulmonary Diseases and Disorders. Alfred P. Fishman, (ed). McGraw Hill, New York, 1997
10. Abolhoda A, Keller SM. Surgical Staging of the Mediastinum. In: Lung Cancer: Principles and Practice. Harvey Pass, ed. J.B. Lippincott Company, Philadelphia, 2000
11. Keller SM, Small Z. Adjuvant therapy for surgically resected stage II and IIIa non-small cell lung cancer. In: Controversies and Issues in Lung Cancer. Benjamin Movsas, Corey Langer, Melvyn Goldberg, eds. Marcel Dekker, Inc., New York, 2001
12. Keller SM. Mediastinal Lymph Node Dissection. In: Thoracic Surgery. F Griffith Pearson, ed. Churchill Livingstone, New York, 2002
13. Keller SM, Nabagiez J. Surgical management of non-small cell lung cancer. In: Atlas of Cancer. Maurie Markmen ed. Lippincott Williams & Wilkins, Philadelphia, 2003
14. Keller SM, Mortmen K. Mediastinal lymph node dissection for lung cancer. In: Current Therapy in Thoracic and Cardiovascular Surgery. Stephen Yang, Duke Cameron, eds. Mosby, Philadelphia, PA, 2004
15. Keller SM, Lin C-C. Surgical Treatment of hyperhidrosis. In: Sabiston and Spencer's Surgery of the Chest. Frank Selke, Pedro del Nido, Scott Swanson, eds. Elsevier Saunders, Philadelphia, 2005
16. Rajdev L, Keller SM. Postoperative Therapy for Resectable Lung Cancer. In: Lung Cancer: Principles and Practice. Harvey I Pass, David P Carbone, John D Minna, David H Johnson, Andrew T Turrisi III, eds. Lippincott Williams and Wilkins, Philadelphia, 2005
17. Rajdev L, Keller SM. Surgery for Lung Cancer in the Elderly. Am Soc Clin Oncol Ed Book 463-467, 2006
18. Bello R, Keller SM. Surgical Staging of Non-Small Cell Lung Cancer. In: Tumors of the Chest: Biology, Diagnosis, and Management. Konstantinos Syrigos, Christopher Nutting, Charalambos Roussos eds. Springer-Verlag (in press)
19. Khoynezhad A, Keller SM. Mediastinal Lymph Node Dissection. In: Mastery of Cardiothoracic Surgery. Larry Kaiser, Irving Kron, Thomas Spray eds. Lippincott Williams & Williams, Philadelphia, 2006
20. Keller SM. Thoracoscopic Surgical Sympathectomy for Hyperhidrosis and Vasomotor Disorders. In: Adult Chest Surgery: Concepts and Procedures. David Sugarbaker ed. McGraw-Hill (in press)
21. Bello R, Keller SM. Mediastinal Lymph node Dissection. In: Pearsons's Textbook of Thoracic and Esophageal Surgery. Alec Patterson ed. Elsevier (in press)
22. Smego D, Nabagiez J, Keller SM. Surgical management of non-small cell lung cancer. In: Atlas of Cancer. Maurie Markmen ed. Lippincott Williams & Wilkins, Philadelphia, (in press)
Abstracts
1. Kaiser LR, Fleshner P, Keller SM. The significance of microscopic residual disease at the bronchial resection margin. Chest 1988;94:845
2. Keller SM, Taylor DD, Weese JL. Photodynamic therapy of human malignant mesothelioma xenografts in nude mice. Proc Am Assoc Cancer Res 1990;31:392
3. Langer CJ, Curran WJ, Blankstein K, Nash S, Keller SM. Phase II evaluation of concurrent 5-fluorouracil cisplatin, etoposide, and thoracic radiation (RT) for locally advanced unresectable non-small cell bronchogenic carcinoma. Proc Am Soc Clin Oncol 1990;9:243
4. Carp NZ, Ellison D, Keller SM. Flow cytometric analysis of DNA content in surgically staged non-small cell lung cancer. Chest 1990;98:62S
5. Langer CJ, Curran WJ, Catalano RB, Fowler WC, Keller SM. Low locoregional relapse rate and significant morbidity observed in a phase II trial of simultaneous thoracic radiation therapy (RT) and multi-agent chemotherapy for locally advanced non-small cell lung cancer (NSCLC). Int J Rad Onc Biol Phys 1991;21:216
6. Testa JR, Miura I, Siegfried JM, Keller SM, Resau J, Zhou J-Y, Cheng J-Q. Chromosome alterations in non-small cell lung cancer. Proc Am Assoc Cancer Res 1991;32:186
7. Sauter E, Keller SM. HER-2/neu Oncoprotein is found adjacent to but not in esophageal adenocarcinoma. Proc Am Assoc Cancer Res 1992;33:1524
8. Hunt JD, Siegfried JM, Zhou J, Keller SM, Testa JR. Cytogenetics of primary non-small cell lung carcinoma using two culture methods. Proc Am Assoc Can Res 1992;33:232
9. Langer C, Curran W, Catalano R, Fowler W, Keller S, Nash S, Blankstein K, Bagchi P, Hanks G, Comis R. Encouraging 2-year survival in phase II trial of simultaneous thoracic radiation therapy (RT) and multi-agent chemotherapy for locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1992;11:999
10. Taguchi T, Zhou JY, Jhanwar SC, Siegfried JM, Tartof KD, Keller SM, Testa JR. Recurrent chromosome losses in human malignant mesothelioma. Proc Am Soc Cancer Res 1992;33:239
11. Curran WJ, Langer CJ, Keller SM, et al. Analysis of clinical trials employing pre-operative chemotherapy and /or thoracic radiation therapy for marginally resectable non-small cell lung cancer. Int j Rad Oncol Biol Phys 1993;27:189
12. Algan Ö, Coia LR, Keller S, Engstrom P, Hanks GE. The role of postchemoradiotherapy esophagectomy in the treatment of adenocarcinoma of the esophagus. Proc Am Soc Clin Oncol 1994;13:627
13. Langer CJ, Curran WJ, Catalano R, Keller S, Blankstein K, Comis R. Long term survival results for patients with locally advanced non-small cell lung carcinoma (NSCLC) treated with aggressive concurrent chemoradiotherapy. Proc Am Soc Clin Oncol 1994;13:1102
14. Testa JR, Liu ZM, Siegfried JM, Hunt JD, Feder S, Litwin S, Keller SM. Recurrent cytogenetic alterations in 63 non-small cell lung carcinomas (NSCLC). Lung Cancer 1994; 11 (suppl 1):054
15. Langer CJ, Curran WJ, Catalano R, Keller SM, Blankstein K, Comis R. Long term survival results for patients with locally advanced non-small cell lung carcinoma (NSCLC) treated with aggressive concurrent chemoradiotherapy. Lung Cancer 1994; 11(suppl 1):688
16. Pisch J, Paglucci, Malamud S, Ross D, Keller S, Beattie E. Interrupted twice a day irradiation with concomitant chemotherapy and GCSF for advance lung cancer. Phase I-II study. Lung Cancer
17. Pisch, Malamud S, Yudelman I, Ross D, Keller S. Pathologic response and resectability after combined modality treatment for stage IIIa and IIIb non-small cell lung cancer. 3rd International Congress on Lung Cancer 1998; 279-83
18. Keller SM, Adak S, Johnson D, et al. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: an intergroup trial (E3590) Proc Am Soc Clin Oncol 1999;18:465a
19. Schiller JH, Adak S, Feins R, Keller S, et al. Prognostic significance of p53 and K-RAS mutations in primary resected non-small cell lung cancer: Preliminary results from a prospective randomized trial of postoperative adjuvant therapy (Intergroup Trial 0115). Proc Am Soc Clin Oncol 1999;18:464a
20. Keller SM, Adak S, Wagner H, et al. Randomized prospective comparison of adjuvant mediastinal radiation (RT) with or without concurrent chemotherapy with cisplatin and etoposide (PE) for patients with completely resected T1-3N1-2M0 non-small cell lung cancer (NSCLC): US lung intergroup trial 0115. Proc ASTRO 1999
21. Goldfarb CR, Guelfguat M, Edelstein Y, Keller S, Criss JS, Onseng F, Finestone H, Turetskiy V, Galynker B, Yaw M. Distribution of bone metastases in lung cancer. Proc Soc Nuc Med 1999; No. 1144
22. Keller SM, Adek S, Wagner H, Johnson DH, for the Eastern Cooperative Oncology Group. Complete mediastinal lymph node dissection improves survival in patients with resected stages II and IIIa non-small cell lung cancer. Proc Soc Thorac Surg 36th Annual Meeting 2000;1
23. Wagner H, Adak S, Keller S, et al. Patterns of failure for patients with resected N1 or N2 non-small cell lung cancer (NSCLC) following mediastinal irradiation with or without concurrent chemotherapy: An analysis of Eastern Cooperative Oncology Group (ECOG) E3590 Proc Am Soc Clin Oncol 2000;19:494a
24. Rosen MJ, Keller SM, Adak S, Wagner H, Johnson DH, and The Eastern Cooperative Oncology Group. Pulmonary function tests (PFT) following adjuvant radiation therapy (RT) or combined chemoradiotherapy (C-RT) in patients with resected stages II and IIIa non-small cell lung cancer (NSCLC). Chest 2000;118 (Number 4/Suppl):232S
25. Keller SM, Adak S, Wagner H, Johnson DH. Gender does not influence tumor recurrence or survival following adjuvant therapy of completely resected stages II and IIIa NSCLC.8th European Conference on General Thoracic Surgery, London, November, 2000. Abstract Book pg 202
26. Keller SM. Mediastinal lymph node dissection improves survival in patients with stage II-IIIa non-small cell lung cancer. J Jap Assoc Chest Surg 2001;15:87
27. Keller SM, Vangel MG, Adak S, Wagner H, Schiller JH, Herskovic A, Komaki R, Perry MC, Marks RS, Livingston, RB and Johnson DH for the Eastern Cooperative Oncology Group. Second Primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Proc Am Soc Clin Oncol 2002;21:301a(abstract 1202)
28. Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic AM, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH. Prolonged survival in patients with resected non-small cell lung cancer (NSCLC) and single level N2 disease. (AATS 2003)
29. Kolesar J, Breunig A, Marsh S, Miller J, Wieman A, Vangel M, McLeod H, Keller SM, Schiller J for the Eastern Cooperative Oncology Group. The NQO1*2/p53wt genotype is a predictor of poor survival in patients who received adjuvant radiation and chemotherapy following resection of stages II and IIIa NSCLC. Proc Am Soc Clin Oncol 2003;22:125 (abstract 499)
30. Wakelee H, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH, for the Eastern Cooperative Oncology Group (ECOG). Adjuvant radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIa non-small cell lung cancer (NSCLC) leads to higher than expected risk of death from intercurrent disease (DID). Proc Am Soc Clin Oncol 2003;23:633(abstract 2545)
31. Halmos B, Basseres D, D`Alo F, Dayaram T, Ferenczi K, Kocher O, Keller SM, Johnson DH, Schiller JH, Huettner CS, Tenen DG. A study of differentiation factors as candidate tumor suppressors in lung cancer. Lung Cancer 2003;41 (Suppl 2):S-216 (poster P-497).
32. Kolesar J, Breunig A, Marsh S, Miller J, Stephenson P, McLeod H, Keller SM, Schiller J. CYP3A5*3B Polymorphism Frequency in NSCLC Tumors is Greater than in Matched Normal Nodes and the Normal Population. NCI EORTC 2003
33. Kolesar JM, Breunig A, Miller J, Stephenson P, McLeod H, Marsh S, Keller S, Johnson D, Schiller JH, Eastern Cooperative Oncology Group. CYP#A5*3 and CYP3A4*1B polymorphisms are associated and more frequent in NSCLC than in normal volunteers. J Clin Oncol 23;2004 (suppl;abstr 2016)
34. Dubey S, Miller J, Stephenson P, Keller SM, Johnson DH, Schiller JH, Kolesar JM, Eastern Cooperative Oncology Group. EGFr dinucleotide repeat polymorphism in non-small cell lung cancer. J Clin Oncol 23;2004 (suppl;abstr 9585)
35. Khandani AH, Whitney KD, Keller SM, Isasi C, Madan R, Blaufox MD. 18-F FDG PET and proliferative activity of stroma in bronchioloalveolar lung cancer. Soc Nuc Med 2004;Abst 1189
36. Karp D, Lee S, Keller S, Johnson D, Kucuk O, Clamon G, Marks R, Johnston M, Okawara G, Ruckdeschel J. Interim report: A phase III randomized double blind chemoprevention trial of selenium supplementation in persons with resected stage I non-small cell lung cancer. Lung Cancer 2005;49(Suppl 2):S181 (abstract P-252)
37. Martin NE, Mick R, Hahn SM, Bernhard EJ, Gupta AK, Schiller J, Keller S, Johnson D, McKenna WG, Farber J. P27 is a molecular tumor marker prognostic for survival in 188 NSCLC patients treated with radiation +/- chemotherapy on ECOG3590. International Radiation Oncology Translational Research Meeting, March 2005
38. Costa DB, Stephenson P, Kocher O, Keller SM, Johnson DH, Schiller JH, Tenen DG, Halmos B. C/EBPα expression by immunohistochemistry lacks prognostic or predictive significance in resected non-small-cell lung cancer. Proc Am Soc Clin Oncol 2006;26:414s (Abstract 7202)
39. Shanske A, Keller SM, .The incidence of Marfan Syndrome (MFS) in young patients who present with spontaneous pneumothorax (SP). (2006 Pediatric Academic Societies' Meeting)
40. Lutz D, Sapkar J, Lopez-Barcons L, Keller S, Perez-Soler R, Locker J. Frequent loss of heterozygosity at 14q13.3 in lung cancer. (Proc Am Assoc Can Res 2006;Abstract 3258)
41. Kleinberg LR, Eapen S, Hamilton S, Keller SM, Forastiere A, Anne P, Benson AB. E1201: An Eastern Cooperative Oncology Group (ECOG) Randomized Phase II Trial to Measure Response Rate and Toxicity of Preoperative Combined Modality Paclitaxel/Cisplatin/RT or Irinotecan/Cisplatin/RT in Adenocarcinoma of the Esophagus. (Submitted ASTRO 2006)
42. Kleinberg L, Powell ME, Forastiere A, Keller S, Hamilton S, Anne P, Benson AB. E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus. Pro Am Soc Clin Oncol 2007;25:205s Abstract 4533)
43. McDaid HM, Legrier, Yang CH, Yan HG, Lopez-Barcons L, Keller SM, Horwitz SB. Combined MEK and mTOR suppression is synergistic in human NSCLC and is mediated via inhibition of protein translation. Pro Am Soc Clin Oncol 2007;25:593s (Abstract 10615)
Presentations
Society of Surgical Oncology - Videotape Session - May 1989 Title: Technique of mediastinal lymph node dissection for the staging of non-small cell lung cancer - Keller SM, and Weese JL. Running time, 17 mins
American College of Surgeons Clinical Congress - Motion Picture Exhibition - October, 1989. Title: Technique of mediastinal lymph node dissection for the staging of non-small cell lung cancer - Keller SM, Weese JL. Running time, 17 mins
XVI World Congress on Diseases of the Chest - American College of Chest Physicians - Motion Picture Session - October 1989. Title: Technique of mediastinal lymph node dissection for the staging of non-small cell lung cancer - Keller SM, Weese JL. Running time, 17 mins
Association of Academic Surgery - Louisville, KY - November 1989. Topic: In-vitro killing of human malignant mesothelioma by photodynamic therapy
American Association for Cancer Research, Inc. - Washington, DC - May, 1990 Poster Session: Photodynamic therapy of human malignant mesothelioma xenografts in nude mice
The Western Thoracic Surgical Association 16th Annual Meeting. San Diego, CA - June, 1990. Adjunctive epidural analgesia for thoracic surgical procedures
The American College of Chest Physicians 56th Scientific Assembly. Toronto, Canada - October, 1990. Flow cytometric analysis of DNA content in surgically staged non-small cell lung cancer
Association of Academic Surgery. Colorado Springs, Colorado November 20-23, 1991. Poster Session: Adriamycin enhanced In vitro and In vivo photodynamic therapy of mesothelioma
Society for Study of Principle of Lung Cancer Surgery. Tokyo, Japan - December 5-10, 1991. Technique of mediastinal lymph node dissection
The University of Colorado School of Medicine. Denver, Colorado - April 3-4, 1992. Lecture: Treatment of the local complications of lung cancer
Society of Surgery of the Alimentary Tract. San Francisco, California - May 11-13, 1992. Poster Session: The clinical implications of p53 oncogene over-expression in patients with esophageal adenocarcinoma
American Association for Cancer Research, San Diego, California, May 21, 1992. Poster Session: HER-2/neu oncoprotein is found adjacent to but not in esophageal adenocarcinoma
American Association for Cancer Research, San Diego, California - May 21, 1992. Poster Session: Cytogenetics of primary non-small cell lung carcinoma using two culture methods
Memorial Sloan-Kettering Cancer Center, Thoracic Surgical Oncology 1993 - A Tribute to Nael Martini, M.D., New York, New York - April 16 - 17, 1993. Lecture: Adjuvant therapies for mesothelioma
International Society of Cardio-Thoracic Surgeons, Jerusalem, Israel, February 20-23, 1994. Oral presentation: Survival Following Resection of Clinically Occult N2 Non-Small-Cell Lung Cancer
International Society of Cardio-Thoracic Surgeons, Jerusalem, Israel, February 20-23, 1994. Poster: Therapy of Severe Post-Thoracotomy Pain
New York Roentgen Society, New York, April 21, 1994. Lecture: Surgery in the Management of Small-Cell Lung Carcinoma
Society of Surgical Oncology, Boston, March 1995. Oral Presentation: P53 correlates with disease progression in patients with non-small cell lung cancer
American Society of Clinical Oncology, Los Angeles, May 1995. Oral presentation: Chemoradiation followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction: Results of a Phase II study of the Eastern Cooperative Oncology Group
New York Cancer Society, New York, April 1998. Oral Presentation: Multi-modality aspects of the treatment of non-small cell lung cancer from the surgeons perspective
First World Conference on Clinical Cooperative Research for Lung Cancer, Brussels, Belgium, March 1999. Oral Presentation: Clinical trials with lung cancer surgery: investigational questions and practical problems
First World Conference on Clinical Cooperative Research for Lung Cancer, Brussels, Belgium, March 1999. Poster presentation: Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: an intergroup trial (E3590)
American Society of Clinical Oncology, Atlanta, April 1999. Oral presentation: Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: an intergroup trial (E3590)
Webcast: Neoadjuvant and adjuvant therapy for non-small cell lung cancer. alphaoncology.com. July 1999
Society of Thoracic Surgeons, January 2000. Maxwell Chamberlain Paper, Oral presentation: Complete mediastinal lymph node dissection improves survival in patients with resected stages II and IIIa non-small cell lung cancer
9th World Conference on Lung Cancer, Tokyo, September 2000. Oral presentation: Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: an intergroup trial (E3590)
8th European Conference on General Thoracic Surgery, London, November 2000. Oral presentation: Gender does not influence tumor recurrence or survival following adjuvant therapy of completely resected stages II and IIIa NSCLC
18th Annual Meeting of the Japanese Association for Chest Surgery, Tokyo, May 2001. Oral presentation: Mediastinal lymph node dissection improves survival in patients with stage II-IIIa non-small cell lung cancer
Roswell Park Cancer Institute Symposium, Treatment of pre-malignant lesions and early lung cancer, Buffalo, New York, June 2001. Oral presentation: Adjuvant treatment strategies in non-small cell lung cancer
10th Annual Meeting of the Spanish Lung Cancer Group, Barcelona, Spain, November 2001. Oral presentation: Treatment of early stage lung cancer
American Society of Clinical Oncology, Washington, DC May 2002. Poster session. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer
Workshop on the Management of Locally Advanced Non-small Cell lung Cancer. Taiwan Lung Cancer Society, Taipei October 2002. Oral presentation: Adjuvant therapy for locally advanced non-small cell lung cancer
American Association for Thoracic Surgery, Boston, Massachusetts, May 2003. Oral presentation: Prolonged survival in patients with resected non-small cell lung cancer (NSCLC) and single level N2 disease.
American Association for Thoracic Surgery, Boston, Massachusetts, May 2003. Post Graduate Course. Management of solitary N2 disease: Primary resection
Third International Workshop on Surgical Exploration of the Mediastinum and Systematic Nodal Dissection. Barcelona, Spain November 2003. Oral presentation: Pro mediastinal lymph node dissection.
19th Annual Japan Cancer Society Workshop. Kyoto, Japan July 2004. Oral presentation: Treatment of early stage non-small cell lung cancer.
American Society of Clinical Oncology, Atlanta, GA June 2006. Educational session. Treating Patients Older than 70 with Non-Small Cell Lung Cancer: Are We Doing Our Best for this Population?
Fourth International Workshop on Surgical Exploration of the Mediastinum and Systematic Nodal Dissection. Barcelona, Spain November 2006. Oral presentation: Pro mediastinal lymph node dissection.
